Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11

This study has been completed.

First Received on April 18, 2001. Last Updated on June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	New York MDRU
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00015301

Purpose

The purpose of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.

Condition	Intervention	Phase
Cocaine-Related Disorders Substance-Related Disorders	Drug: Methylphenidate	Phase IV

Study Type:	Interventional
Study Design:	Masking: Double-Blind Primary Purpose: Diagnostic
Official Title:	Methylphenidate Raclopride PET Test

Resource links provided by NLM:

MedlinePlus related topics: Drug Abuse

Drug Information available for: Raclopride Methylphenidate Methylphenidate hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Dopamine receptor availability

Estimated Enrollment:

Detailed Description:

The objective of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Healthy normals

Exclusion Criteria:

History of head trauma or loss of consciousness. Significant medical history. History of seizures.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00015301

Locations

United States, New York
New York MDRU
New York, New York, United States, 10010

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

New York MDRU

Investigators

Principal Investigator:

John Rotrosen, M.D.

New York MDRU

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00015301 History of Changes
Other Study ID Numbers:	NIDA-5-0013-11, Y01-5-0013-11
Study First Received:	April 18, 2001
Last Updated:	June 23, 2005
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Methylphenidate
Raclopride
Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs
Central Nervous System Stimulants
Central Nervous System Agents
Therapeutic Uses
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists

ClinicalTrials.gov processed this record on February 09, 2012